1.2Fixed fused ring junction
A fused bicyclic scaffold shares a carbon–carbon bond between its two rings. The shared bond limits rotation at the junction and fixes the relative orientation of substituents on the two rings.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A fused bicyclic scaffold shares a carbon–carbon bond between its two rings. The shared bond limits rotation at the junction and fixes the relative orientation of substituents on the two rings.
A thioether sulfur joins the two neighboring ring carbons. The sulfur provides a polarizable contact surface, and its carbon–sulfur bonds increase the spacing between the neighboring carbons relative to an ether linkage.
The difluoromethylene carbon connects the same two neighboring atoms through single bonds. Its two carbon–fluorine bonds change the local electrostatic surface while retaining a single tetrahedral atom at the linkage.
The nitrile attaches through its carbon and projects a linear carbon–nitrogen triple bond from the scaffold. The terminal nitrogen accepts a hydrogen bond when the pocket places a donor along the nitrile axis.
The substituent attaches through sulfur in an A–S(═O)₂–CH₃ linkage. The two sulfonyl oxygens provide hydrogen-bond acceptor sites, and the terminal methyl group occupies a small nonpolar volume.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary oncology laboratory places tumor cells from canine mammary biopsies in low-attachment culture wells. The laboratory adds the compound to test wells and vehicle alone to matched control wells. The assay measures spheroid number, spheroid diameter, and viable cell count to distinguish changes in aggregation from changes in cell number.
Gold microelectrodes replace the linked detectable moiety as the source of the assay signal. Tumor cells settle onto extracellular matrix-coated electrodes in wells that receive the compound or vehicle. The reader records impedance before and after exposure, and matched wells provide cell viability measurements to help interpret changes in electrode coverage.
A 96-well low-attachment plate holds 2,000 tumor cells per well in 100 microliters of medium. Triplicate wells receive the compound at 0.03, 0.1, 0.3, 1, 3, or 10 micromolar with the same final vehicle concentration, and matched wells receive vehicle alone. A bright-field microscope records images at 0, 24, and 72 hours for measurement of spheroid count and projected area.
A two-channel microfluidic chip places a collagen gel between a tumor cell channel and a perfusion channel. The perfusion channel carries medium containing the compound, and a matched chip receives medium with vehicle alone. Time-lapse microscopy tracks cells crossing the tumor–gel interface and measures their penetration depth over time.
A tumor microdialysis probe connects to a low-flow pump and a timed fraction collector in an in vivo study. After compound administration, the probe collects serial samples of tumor extracellular fluid, and liquid chromatography coupled to tandem mass spectrometry quantifies the compound in each fraction. Probe recovery calibration converts the measured concentrations into estimates of extracellular exposure, which are aligned with the times of tumor imaging.
A motorized microscope acquires time-lapse phase-contrast images of compound-treated and vehicle-treated spheroids embedded in a transparent matrix. Software segments the initial spheroid boundary, detects cells that leave it, and links detections between frames by spatial proximity. The software reports the number of departing cells, their speeds, and their radial displacements from the initial boundary.
X1 is N(H)₀ at a pyridine-like position in a six-membered aromatic ring. In the neutral form, its lone pair lies in the ring plane and accepts a hydrogen bond.
Both R8 groups are methyl in an —N(R8)₂ substituent, giving an —N(CH₃)₂ group. The nitrogen has two methyl bonds and one bond to the scaffold, and it accepts a proton under acidic conditions.
X2 is C(H)₂, with m set to 2. The carbon forms two single bonds to its neighbors and carries two hydrogens in a saturated ring segment.
The value of t is 2 in an R6 group of the form —S(═O)₂–NH–CH₂–phenyl. The sulfonyl oxygens act as hydrogen-bond acceptors, and the nitrogen carries one hydrogen and connects to the phenyl ring through a methylene group.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A method of treating a neurological disease selected from multiple sclerosis and psoriasis by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein: R1 is C1-C6 alkyl;B · US 9,604,922 B2 · claim 8
La is C1-C6 alkyl, C3-C10 carbocycle, C6-C10 aryl, heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, wherein the alkyl, carbocycle, aryl, heterocycle, or heteroaryl groups are optionally, independently substituted one or more times with halogen;B · US 9,604,922 B2 · claim 8
In the formula (1), A1, A2, A3 and A4 independently represent a carbon or nitrogen, and it is necessary that at least one of these represents a carbon.A · US 2009/0252680 A1 · ¶ 23
A compound represented by the following formula (1), or a salt thereof: wherein each of A1, A2, A3 and A4 independently represents a carbon or nitrogen, R1 is a group selected from the group consisting of hydrogen, hydroxyl group, carboxyl group, sulfuric acid group, amino group, nitro group, cyano group, non-radioactive halogen substituents, alkyl substituents with 1-4 carbon atoms, and alkoxy substituents with 1-4 carbon atoms, and R2 is a radioactive halogen substituent, pA · US 2009/0252680 A1 · claim 1
R2 is C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, C6-C10 aryl, C3-C10 carbocycle, heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, wherein the alkyl, alkenyl, alkynyl, aryl, carbocycle, heterocycle, or heteroaryl groups are optionally, independently substituted one or more times with C1-C6 alkyl, OH, O(C1-C6 alkyl), oxoB · US 9,604,922 B2 · claim 8
R2 is C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, C6-C10 aryl, C3-C10 carbocycle, heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, wherein the alkyl, alkenyl, alkynyl, aryl, carbocycle, heterocycle, or heteroaryl groups are optionally, independently substituted one or more times with C1-C6 alkyl, OH, O(C1-C6 alkyl), oxoB · US 9,604,922 B2 · claim 8
R3 is H, C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, SO2R4, or S(O)R4, wherein the alkyl, alkenyl, or alkynyl groups are optionally, independently substituted one or more times with C1-C6 alkyl, OH, O(C1-C6 alkyl), oxo, halogen, NH2, N(H)(C1-C6 alkyl), N(C1-C6 alkyl)2, SO2H, SO2(C1-C6 alkyl), CHO, CO2H, CO2(C1-C6 alkyl), or CN;B · US 9,604,922 B2 · claim 8
An empty cell means only that no passage was reproduced there.
More specifically, the invention relates to a compound useful for amyloid detection at lesion sites in diagnosis of Alzheimer's disease and other diseases with amyloid accumulation.A · US 2009/0252680 A1 · ¶ 1
At present, it is practically impossible to establish a definite diagnosis of AD while an AD patient is still alive, because the definite diagnosis requires a biopsy of a lesion (Non-Patent Document 1).A · US 2009/0252680 A1 · ¶ 5
For example, dimethyl fumarate is known to cause side effects upon oral administration, such as flushing and gastrointestinal events including nausea, diarrhea, and/or upper abdominal pain in subjects.B · US 9,604,922 B2 · ¶ 7
Further, in the use of a drug for long-term therapy, it is desirable that the drug be formulated so that it is suitable for once- or twice-daily administration to aid patient compliance.B · US 9,604,922 B2 · ¶ 7
patent.fyi, US 2026/0355168 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355168/, SHA-256 e5ded41b090e159326c773fd7f445ac262a36c9f8cfb0b087f314af91425f61b